In vivo glioma models, which are extremely useful tools to study tumorigenesis [16], indicated that IDH mutations by themselves, despite being early events, are not sufficient to drive tumorigenesis, making the involvement of other molecular players necessary [17]. The gene discussed is IDH1; the disease is central nervous system cancer.